跳到正文
研踪PaperTrail

论文库

检索计算机领域论文,按研究方向、作者或关键词筛选。

部分采集异常
正在读取账号与研究记录…

全站更新概况

+1958新增论文
+1549其中 AI 相关
+213已有论文修订
+95新增 AI 导读

arXiv 最近完成扫描:2026-11-17 19:15 · 全站最近入库:2026-11-17 20:18各信源进度 →

统计口径与数据新鲜度

统计 2026-11-16 20:25 — 2026-11-17 20:25(北京时间) · 点击数字查看对应简报;AI 相关包含在新增论文内。

最近完成检查:2026-11-17 19:15最近发现新增版本:2026-11-17 20:18库内论文最新更新时间:2026-11-17 02:59

每分钟刷新已保存的数据。空检查不代表采集异常;新收录可能包含历史论文。AI 导读按新增版本计数。

25,785 已收录论文21,490 AI 相关7,725 有修订112 HF 社区发现

浏览论文库

时间范围跟随排序:版本更新、本站收录或首次发表。最新收录可能包含历史论文。部分信源异常,查看状态 →

找到 1 篇论文 · 按版本更新时间排序上轮扫描起点 2026-11-17 19:14(北京时间)
新论文 · v1arXiv:2611.10145

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

Omar Ibrahim, Grant Hamblin, Benjamin Haibe-Kains

原文摘要

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.

cs.LG